P1.09-33 Validity of Non-Small Cell Lung Cancer Not Otherwise Specified to Use Immunohistochemistry on Treatment Outcome

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.809
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung Cancer

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2015English

On the Pharmacogenetics of Non-Small Cell Lung Cancer Treatment

Expert Opinion on Drug Metabolism and Toxicology
MedicineToxicologyPharmacology
2016English

P1.09-36 Clinical Significance of Cannabinoid Receptor CB2 Expression in Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Individualization of Treatment in Non-Small Cell Lung Cancer

F1000 Medicine Reports
2009English

Clinical Outcome of Node-Negative Oligometastatic Non-Small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2016English

Proteomic Profiling Identifies Outcome-Predictive Markers in Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified

Blood advances
Hematology
2018English

Afatinib Treatment in Advanced Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2011English

Real-World Data on Nivolumab Treatment of Non-Small Cell Lung Cancer

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2016English

Programmed Death-Ligand 1 Immunohistochemistry Testing for Non-Small Cell Lung Cancer in Practice

Cancer cytopathology
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy